Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • November 2018
  • Case
  • HBS Case Collection

David Hysong and SHEPHERD Therapeutics

By: Ananth Raman, John Masko and Aldo Sesia
  • Format:Print
  • | Language:English
  • | Pages:24
ShareBar

Abstract

In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his and other rare cancers. Two years later, the company had several drugs in promising stages of development but were at least 3 to 5 years away from commercialization, if they made it through clinical trials successfully. Only about 4% of drugs that enter clinical trials receive U.S. FDA approval. It is October 2018, and Shepherd is running out of money. Hysong needs to raise $5 million to fund operations for 2019 and at least $20 million for the following few years. But the company is too early to attract the type of venture capital he needs. Even if he got financing, Hysong worried that the company’s mission could be compromised by investors more interested in a return on their investment than saving lives, and he worried about the scaling challenges ahead.

Keywords

Cancer; Therapeutics; Drugs; Health Care And Treatment; Business Startups; Product Development; Financing And Loans; Growth And Development Strategy; Problems And Challenges

Citation

Raman, Ananth, John Masko, and Aldo Sesia. "David Hysong and SHEPHERD Therapeutics." Harvard Business School Case 619-012, November 2018.
  • Educators

About The Author

Ananth Raman

Technology and Operations Management
→More Publications

More from the Authors

    • February 2021
    • Faculty Research

    Barbarians at the Gate or Turnaround Gurus? Private Equity and the Rise of the LBO

    By: Tom Nicholas and John Masko
    • January 2021
    • Faculty Research

    Hester Pharmaceuticals (A): A Pricing Dilemma

    By: Dante Roscini and John Masko
    • November 2020
    • Faculty Research

    Unrest in Chile

    By: Vincent Pons, John Masko, Rafael Di Tella and William Mullins
More from the Authors
  • Barbarians at the Gate or Turnaround Gurus? Private Equity and the Rise of the LBO By: Tom Nicholas and John Masko
  • Hester Pharmaceuticals (A): A Pricing Dilemma By: Dante Roscini and John Masko
  • Unrest in Chile By: Vincent Pons, John Masko, Rafael Di Tella and William Mullins
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Digital Accessibility
Copyright © President & Fellows of Harvard College